# NCT04404660 (NCT04404660)

> A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04404660
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Autolus Limited
- Conditions: Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
- Interventions: AUTO1
- Enrollment: 153
- Primary outcome: Phase 1b - Frequency and severity of adverse events (AEs) and serious adverse events (SAEs) occurring after AUTO1 infusion
- Primary outcome: Phase 2 - Cohort IIA: ORR defined as proportion of patients achieving CR or CRi as assessed by an IRRC.

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Bluesky threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct04404660